There is at present an open clinical trial combining the HDAC6 specific HDAC inhibitor ACY-241 with Ipilimumab (anti-CTLA4) and Nivolumab (anti-PD-1) for melanoma (NCT02935790). Here, HDAC9 is linked to melanoma.